HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR
申请人:Grandel Roland
公开号:US20100048582A1
公开(公告)日:2010-02-25
The invention relates to compounds of the formula (I)
wherein the variables have meanings given in the claims and the description.
The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT
6
receptor ligand.
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
申请人:Grandel Roland
公开号:US08497273B2
公开(公告)日:2013-07-30
The invention relates to compounds of the formula (I)
wherein the variables have meanings given in the claims and the description.
The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT6 receptor ligand.
[EN] HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUVANT ÊTRE UTILISÉS POUR TRAITER DES TROUBLES QUI RÉPONDENT À LA MODULATION DU RÉCEPTEUR DE SÉROTONINE 5HT6
申请人:ABBOTT GMBH & CO KG
公开号:WO2007118900A1
公开(公告)日:2007-10-25
[EN] The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT6 receptor ligand. [FR] La présente invention concerne des composés de formule (I) dans laquelle les variables ont les significations données dans les revendications et la description. L'invention concerne également l'utilisation d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci, pour préparer un médicament destiné à traiter un problème de santé qui répond au traitement avec un ligand du récepteur 5HT6.